Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10283547 | 0.93 | NR1H2 (0.51) | NR1H2HPGDPDE4BBRD4EPHX1 | |
| SCHEMBL88863 | 0.93 | NR1H2 (0.51) | NR1H2HPGDPDE4BBRD4EPHX1 | |
| SCHEMBL30306795 | 0.93 | NR1H2 (0.51) | NR1H2HPGDPDE4BBRD4EPHX1 | |
| SCHEMBL18275027 | 0.93 | HPGD (0.50) | NR1H2HPGDPDE4BEPHX1SMN1; SMN2 | |
| SCHEMBL4667718 | 0.93 | NR1H2 (0.51) | NR1H2HPGDPDE4BBRD4EPHX1 | |
| SCHEMBL13461241 | 0.93 | NR1H2 (0.51) | NR1H2HPGDPDE4BBRD4EPHX1 | |
| SCHEMBL89018 | 0.93 | NR1H2 (0.51) | NR1H2HPGDPDE4BBRD4EPHX1 | |
| SCHEMBL55897 | 0.93 | NR1H2 (0.51) | NR1H2HPGDPDE4BBRD4EPHX1 | |
| SCHEMBL29152507 | 0.89 | NR1H2 (0.53) | NR1H2HPGDPDE4BEPHX1SMN1; SMN2 | |
| SCHEMBL24534930 | 0.87 | NR1H2 (0.47) | NR1H2HPGDPDE4BBRD4EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018108954-A1 | PROCESS FOR THE PREPARATION OF 2-(3-(FLUOROMETHYL)AZETIDIN-1-YL)ETHAN-1-OL | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-21 | — | — | WO | claimed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-02-12 | — | — | US | disclosed |
| EP-4680609-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4371987-B9 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12466823-B2 | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-11-11 | — | — | US | disclosed |
| EP-4371987-B1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4610260-A1 | ARYL HETEROCYCLIC KV1.3 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Shenshi Wise Technology Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| EP-1786785-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| WO-2006041797-A2 | ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2006021884-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050256096-A1 | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes | CUMBRE INC. (US) | 2005-11-17 | — | — | US | disclosed |
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1490043-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082190-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, MAP3K19 | NR1H2 3288/4885HPGD 3838/4885PDE4B 3596/4885 |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | ALK, MET, ERBB2 | NR1H2 4398/4885HPGD 4843/4885PDE4B 3468/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | NR1H2 2697/4885HPGD 4547/4885PDE4B 2171/4885 |
| US-20050256096-A1 | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes | CHCHD6, NAT10, RPS25 | NR1H2 2525/4885HPGD 2593/4885PDE4B 2326/4885 |
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | FAR1, CYP4A11, CYP11B1 | NR1H2 83/4885HPGD 1489/4885PDE4B 1806/4885 |
| US-12466823-B2 | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | RET, REL, GOT1 | NR1H2 182/4885HPGD 1564/4885PDE4B 984/4885 |
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | CNR1, CNR2, MAG | NR1H2 81/4885HPGD 2791/4885PDE4B 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.